<DOC>
	<DOCNO>NCT02586402</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy multiple intravenous dos pegol-Sihematide participant chronic kidney disease ( CKD ) dialysis .</brief_summary>
	<brief_title>Safety &amp; Efficacy Pegolsihematide Treatment Anemia Participants Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>1 . Males females≥18 and≤70 , Weight ≥ 45 kilogram ( kg ) 2 . Participants chronic renal failure dialysis ≥ 3 month prior randomization . 3 . On ESAs treatment ≥8 week prior randomization stable dos average dos ≤ 10000 IU/week 4 . Hemoglobin value ≥ 10.0 and≤ 12.0 g/dL Screening 5 . Patients transferrin saturation≥ 20 % ferritin≥ 100 ng/mL . vitamin B12 folic acid level lower limit normal . 6 . Signed informed consent 1 . Pregnant lactating female 2 . Red blood cell transfusion within 3 month prior randomization 3 . Known intolerance erythropoiesis stimulate agent ( ESA ) pegylated molecule parenteral iron supplementation product 4. hemolytic syndrome coagulation disorder 5. hematological disease ( include limit myelodysplastic syndrome , hematological malignancy , , hemoglobinopathy , pure red cell aplasia ) , 6 . Chronic , uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) ; 7 . C Reactive Protein ( CRP ) great 30 mg/L within 4 week prior randomization 8 . Uncontrolled symptomatic secondary hyperparathyroidism ( iPTH &gt; 800pg/ml ) 9 . Poorly control hypertension within 4 week prior randomization 10 . Chronic congestive heart failure ( New York Heart Association Class Ⅲ IV ) 11. significant symptom within 6 month prior randomization ( e.g . myocardial infarction , serious precarious coronary artery disease , stroke , respiratory disease , autoimmune disease , neuropathy , phrenopathy , hepatopathy include Active hepatitis B , Active hepatitis C , A positive test HIV antibody ALT &gt; 2 x upper limit normal ( ULN ) , AST &gt; 2 x upper limit normal ( ULN ) ) 12. tumor malignancy 13 . Expected survival le 12 month 14 . A scheduled kidney transplant 15 . Major surgery ( may Massive bleeding ) study 16. expect conception within 4 Weeks end Study Treatment 17 . The subject participate clinical trial within 12 week prior randomization 18 . Have condition prior therapy , investigator 's opinion , would make subject unsuitable study , unable unwilling comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>ESAs CKD</keyword>
</DOC>